Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.26 | 18.55 | 37.84 | 18.41 | 32.88 | 24.73 | 16.82 | 24.60 | 26.05 | 18.73 | 23.50 | 15.30 |
| Expenses | 31.60 | 20.46 | 34.48 | 20.12 | 30.60 | 26.88 | 17.52 | 23.95 | 25.97 | 21.41 | 20.82 | 17.25 |
| Operating Profit | 1.66 | -1.91 | 3.36 | -1.71 | 2.28 | -2.15 | -0.70 | 0.65 | 0.08 | -2.68 | 2.68 | -1.95 |
| OPM % | 4.99% | -10.30% | 8.88% | -9.29% | 6.93% | -8.69% | -4.16% | 2.64% | 0.31% | -14.31% | 11.40% | -12.75% |
| Other Income | 0.22 | -0.03 | -1.55 | 1.28 | 0.35 | -0.27 | 0.65 | 0.09 | 0.12 | 0.16 | 0.17 | 0.11 |
| Interest | 2.29 | 2.51 | 3.84 | 2.08 | 2.18 | 2.00 | 2.42 | 1.94 | 1.89 | 1.93 | 2.18 | 2.24 |
| Depreciation | 2.22 | 1.91 | 2.05 | 1.63 | 1.74 | 1.96 | 1.42 | 1.53 | 1.52 | 1.51 | 1.77 | 1.50 |
| Profit before tax | -2.63 | -6.36 | -4.08 | -4.14 | -1.29 | -6.38 | -3.89 | -2.73 | -3.21 | -5.96 | -1.10 | -5.58 |
| Tax % | -12.17% | -6.92% | -10.54% | -25.85% | 62.02% | -18.65% | -47.04% | -26.74% | -8.41% | -20.30% | 25.45% | -24.01% |
| Net Profit | -2.32 | -5.93 | -3.65 | -3.07 | -2.09 | -5.19 | -2.06 | -2.01 | -2.95 | -4.75 | -1.38 | -4.24 |
| EPS in Rs | -1.78 | -4.54 | -2.80 | -2.35 | -1.60 | -3.97 | -1.58 | -1.54 | -2.26 | -3.64 | -1.06 | -3.25 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 154 | 354 | 220 | 145 | 93 | 93 | 84 |
| Expenses | 140 | 286 | 205 | 135 | 94 | 92 | 85 |
| Operating Profit | 14 | 68 | 15 | 10 | -1 | 1 | -2 |
| OPM % | 9% | 19% | 7% | 7% | -1.6% | 0.8% | -2.2% |
| Other Income | 1 | 1 | 10 | -1 | 2 | 1 | 1 |
| Interest | 4 | 9 | 12 | 11 | 9 | 8 | 8 |
| Depreciation | 1 | 6 | 9 | 8 | 7 | 6 | 6 |
| Profit before tax | 10 | 54 | 3 | -11 | -16 | -13 | -16 |
| Tax % | 31% | 25% | 110% | -5% | -21% | -15% | |
| Net Profit | 7 | 40 | -0 | -10 | -12 | -11 | -13 |
| EPS in Rs | 5.26 | 31.02 | -0.20 | -7.77 | -9.50 | -8.49 | -10.21 |
| Dividend Payout % | 0% | 3% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | -10% | -25% | -16% | ||
| Compounded Profit Growth | % | % | % | -17% | ||
| Stock Price CAGR | % | -32% | -17% | 28% | ||
| Return on Equity | % | 2% | -15% | -19% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 10 | 13 | 13 | 13 | 13 | |
| Reserves | 73 | 73 | 63 | 51 | 40 | |
| Borrowings | 77 | 71 | 73 | 83 | 79 | |
| Other Liabilities | 130 | 119 | 92 | 82 | 77 | |
| Total Liabilities | 290 | 276 | 241 | 230 | 209 | |
| Fixed Assets | 93 | 88 | 58 | 57 | 51 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | |
| Investments | 0 | 0 | 0 | 0 | 0 | |
| Other Assets | 198 | 188 | 183 | 172 | 158 | |
| Total Assets | 290 | 276 | 241 | 230 | 209 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | 25 | 26 | -9 | -0 | 11 | |
| Cash from Investing Activity | -44 | -9 | 20 | -2 | 1 | |
| Cash from Financing Activity | 20 | -17 | -10 | 2 | -12 | |
| Net Cash Flow | 0 | -0 | -0 | -0 | 0 | |
| Free Cash Flow | -17 | 16 | 9 | -4 | 11 | |
| CFO/OP | 37% | 202% | 39% | -272% | 1,559% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 105 | 138 | 184 | 262 | 267 | |
| Inventory Days | 59 | 118 | 183 | 331 | 279 | |
| Days Payable | 113 | 165 | 254 | 405 | 317 | |
| Cash Conversion Cycle | 51 | 91 | 113 | 189 | 229 | |
| Working Capital Days | 20 | 24 | 58 | 55 | -30 | |
| ROCE % | 9% | 1% | -4% | -4% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% | 70.60% |
| Public | 29.41% | 29.39% | 29.39% | 29.39% | 29.39% | 29.39% | 29.39% | 29.40% | 29.40% | 29.41% | 29.40% | 29.40% |
| No. of Shareholders | 7,055 | 6,918 | 6,868 | 6,631 | 6,468 | 6,517 | 6,508 | 6,400 | 6,273 | 6,084 | 5,952 | 5,946 |
Fundamentals
Market Cap₹ 52.6 Cr.
Current Price₹ 40.2
Book Value₹ 40.5
ROCE-3.64 %
ROE-19.0 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-16%
Compounded Profit Growth (TTM)-17%
Consolidated figures.
Valuation
Market capRs 42 Cr
Enterprise valueRs 112 Cr
Price to book0.50x
Price to sales0.50x
EV / sales1.34x
Price to cash flow1.69x
Earnings yield-31.98%
Dividend yield2.50%
Profitability
Operating margin (excl. other income)19.21%
Operating margin (incl. other income)19.43%
EBITDA margin-1.57%
Pre-tax margin-18.96%
Net profit margin-15.94%
Net margin, latest quarter-27.71%
ROE48.13%
ROCE39.14%
ROA13.88%
ROIC (approx.)-3.72%
Tax rate24.65%
Other income / net worth0.94%
Growth
Sales growth (latest year)129.34%
Profit growth (latest year)489.47%
Sales growth QoQ-34.89%
Sales growth YoY (latest quarter)-37.80%
Per share
EPS (TTM)Rs -12.85
EPS (latest year)Rs 38.89
EPS (latest quarter)Rs -4.09
Book value per shareRs 80.81
Sales per shareRs 80.62
Cash flow per shareRs 23.85
Free cash flow per shareRs 10.61
Dividend per share (latest year)Rs 1.00
Dividends
Dividend payout2.58%
Efficiency
Asset turnover1.22x
Fixed asset turnover3.82x
Inventory turnover6.59x
Inventory days55 days
Debtor days105 days
Debtors turnover3.47x
Creditor days317 days
Cash conversion cycle229 days
Working capital days-30 days
Leverage
Total debtRs 77 Cr
Cash and bankRs 7 Cr
Net debtRs 70 Cr
Debt to equity0.92x
Interest coverage-0.92x
Owners' fund to total sources28.85%
Debt to assets26.51%
Cash flow
Cash from Operating Activity (latest year)Rs 25 Cr
Cash from Investing Activity (latest year)Rs -44 Cr
Cash from Financing Activity (latest year)Rs 20 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs 11 Cr
Cash from ops / profit, 5 years7.57x
Sales to cash flow14.32x
Statement figures
Net sales (TTM)Rs 84 Cr
Net sales (latest year)Rs 354 Cr
Sales (latest quarter)Rs 15 Cr
Operating profit excl. other income (latest year)Rs 68 Cr
Operating profit (latest quarter)Rs -2 Cr
Other income (TTM)Rs 1 Cr
EBITDA (TTM)Rs -1 Cr
PBDT (TTM)Rs -10 Cr
Profit before tax (TTM)Rs -16 Cr
Tax (latest year)Rs 13 Cr
Net profit (TTM)Rs -13 Cr
Net profit (latest year)Rs 40 Cr
Net profit (latest quarter)Rs -4 Cr
Depreciation (TTM)Rs 6 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 8 Cr
Cost of goods sold (latest year)Rs 243 Cr
Total expenditure (latest year)Rs 286 Cr
Total income (latest year)Rs 355 Cr
Share capitalRs 10 Cr
ReservesRs 73 Cr
Shareholders' fundsRs 84 Cr
Total assetsRs 290 Cr
Net blockRs 93 Cr
InvestmentsRs 0 Cr
ReceivablesRs 102 Cr
InventoryRs 37 Cr
Other liabilitiesRs 130 Cr
Shares outstanding (crore)1.04
Ownership
Promoter holding70.60% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | 540694 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +1.7% | -2.8% | +4.5 pts |
| 1 month | +37.1% | -6.8% | +43.9 pts |
| 3 months | +3.9% | -7.6% | +11.5 pts |
| 3 years | -43.6% | +14.2% | -57.8 pts |
| 5 years | -86.3% | +27.9% | -114.2 pts |
Red flags
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹15 Cr -37.8% vs Jun 2025.
Net loss ₹4 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd (540694) has a market capitalisation of Rs 52.6 Cr. at the 2026-10-01 close.
What were ANG Lifesciences India Ltd's latest quarterly results?
In the Jun 2026 quarter, ANG Lifesciences India Ltd sales was Rs 15 Cr (-37.8% vs Jun 2025) with a net loss of Rs 4 Cr.